fh1

FH1 (NSC-12407) (BRD-K4477), a small molecule, enhances the functions of hepatocytes and promotes differentiation hepatocytes derived by iPS.

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antivirals to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has not been convincingly implicated in cases of clinically apparent liver injury with jaundice.

Norgestrel (WY-3707) is a synthetic progestin commonly used alone or in combination with an estrogen for contraception. Norgestrel suppresses the secretion of luteinizing and follicle-stimulating hormones (LH and FSH), thickens cervical mucus, and slows the transit of ova through the fallopian tubes.

Daclatasvir (EBP 883) (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.

Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody targeting complement protein C5, combined with the domains 1-5 of complement factor H (FH1-5). It exhibits anti-inflammatory and immunomodulatory properties. The isotype control for Vensobafusp alfa can be referred to as human IgG4(S228P) kappa.